The pediatric heart network's study on long-term outcomes of children with HLHS and the impact of Norwood Shunt type in the single ventricle reconstruction trial cohort (SVRIII): Design and adaptations

التفاصيل البيبلوغرافية
العنوان: The pediatric heart network's study on long-term outcomes of children with HLHS and the impact of Norwood Shunt type in the single ventricle reconstruction trial cohort (SVRIII): Design and adaptations
المؤلفون: Caren S. Goldberg, J. William Gaynor, William T. Mahle, Chitra Ravishankar, Peter Frommelt, Dawn Ilardi, David Bellinger, Stephen Paridon, Michael Taylor, Kevin D. Hill, L. LuAnn Minich, Steven Schwartz, Katherine Afton, Melissa Lamberti, Felicia L. Trachtenberg, Russell Gongwer, Andrew Atz, Kristin M. Burns, Shahryar Chowdhury, James Cnota, Jon Detterich, Michele Frommelt, Jeffrey P. Jacobs, Thomas A. Miller, Richard G. Ohye, Christian Pizarro, Amee Shah, Patricia Walters, Jane W. Newburger
المصدر: American heart journal. 254
سنة النشر: 2022
مصطلحات موضوعية: Treatment Outcome, Adolescent, Heart Ventricles, Hypoplastic Left Heart Syndrome, Ventricular Function, Right, Infant, Humans, Stroke Volume, Pulmonary Artery, Cardiology and Cardiovascular Medicine, Child, Norwood Procedures, Univentricular Heart
الوصف: The Single Ventricle Reconstruction (SVR) Trial was the first randomized clinical trial of a surgical approach for treatment of congenital heart disease. Infants with hypoplastic left heart syndrome (HLHS) and other single right ventricle (RV) anomalies were randomized to a modified Blalock Taussig Thomas shunt (mBTTS) or a right-ventricular-to-pulmonary-artery shunt (RVPAS) at the time of the Norwood procedure. The aim of the Long-term Outcomes of Children with HLHS and the Impact of Norwood Shunt Type (SVR III) study is to compare early adolescent outcomes including measures of cardiac function, transplant-free survival, and neurodevelopment, between those who received a mBTTS and those who received an RVPAS.Transplant-free survivors of the SVR cohort were enrolled at 10 to 15 years of age for multifaceted in-person evaluation of cardiac function (cardiac magnetic resonance [CMR], echocardiogram and exercise test) and neurodevelopmental evaluation. Right ventricular ejection fraction measured by CMR served as the primary outcome. Development of arrhythmias, protein losing enteropathy, and other comorbidities were assessed through annual medical history interview. Through the course of SVR III, protocol modifications to engage SVR trial participants were designed to enhance recruitment and retention.Evaluation of long-term outcomes will provide important data to inform decisions about the shunt type placed at the Norwood operation and will improve the understanding of cardiovascular and neurodevelopmental outcomes for early adolescents with HLHS.
تدمد: 1097-6744
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5feb971650b5c8f87165124bbbdb53b9
https://pubmed.ncbi.nlm.nih.gov/36115392
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....5feb971650b5c8f87165124bbbdb53b9
قاعدة البيانات: OpenAIRE